Browse
Submit Data
Databases
API
Help

Dataset Information

6 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Study on the combined scheme of Quxie Capsule in the third-line treatment of metastatic colorectal cancer and the characteristics of the dominant population

ABSTRACT: Interventions: Treatment group:Quxie capsule + Furaquitinib + Regofini + TAS-102;control group:Furaquitinib + Regofini + TAS-102 Primary outcome(s): overall survival (OS) Study Design: Non randomized control

DISEASE(S): Colorectal Cancer

PROVIDER: 41729 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Study on the dominant population of Quxie Capsule in different clinical pathways of metastatic colorectal cancer

Project description:Interventions: Group 1:Standard chemotherapy + Quxie Capsule;Group 2:Maintenance treatment + Quxie Capsule;Group 3:Single drug chemotherapy or targeted therapy + Quxie Capsule;Group 4:Simple TCM treatment + Quxie Capsule Primary outcome(s): Overall survival Study Design: Single arm

| 2760554 | ecrin-mdr-crc

A phase II study of guadecitabien combined with irinotecan vs regorafenib or TAS-102 in previously treated metastatic colorectal cancer patients

Project description:A phase II study of guadecitabien combined with irinotecan vs regorafenib or TAS-102 in previously treated metastatic colorectal cancer patients

2023-03-31 | GSE226221 | GEO

TAS-102, Irinotecan, and Bevacizumab in Pre-treated Metastatic Colorectal Cancer (TABAsCO), A Phase II Clinical Trial. ClinicalTrials.gov NCT04109924

Project description:Background: The efficacy of FOLFIRI plus an antiangiogenesis biologic agent as 2nd line therapy for metastatic colorectal adenocarcinoma is limited. TAS-102 is a novel oral antimetabolite with a distinct mechanism of action from fluoropyrimidines. We evaluated the antitumor efficacy of TAS-102, irinotecan and bevacizumab in patients with pre-treated, advanced colorectal adenocarcinoma in a multicenter, phase II, single-arm study. Methods: Patients with advanced colorectal adenocarcinoma who had progressed after oxaliplatin and fluoropyrimidine and were eligible for treatment with bevacizumab were treated with irinotecan, bevacizumab, and TAS-102 in 28-day cycles. The primary endpoint was progression-free survival (PFS). Results: We enrolled 35 evaluable patients. The study was positive. The median PFS was 7.9 (90% CI 6.2-11.8) months (vs. 6 months in historical control, p=0.018). The median overall survival was 16.5 (90% CI 9.8-17.5) months. Sixty-seven percent of patients experienced grade 3 or higher treatment-related adverse events. The most common toxicities were hematological (neutropenia) and gastrointestinal (diarrhea, nausea, and vomiting). Conclusions: Irinotecan, TAS-102 and bevacizumab is an active 2nd line therapy for patients with metastatic colorectal adenocarcinoma. Neutropenia is common and can affect dose density/intensity mandating use of G-CSF. A randomized study versus standard of care therapy is warranted.

2024-08-26 | GSE275628 | GEO

Follow-up of a randomized, double-blind, controlled clinical study on reducing postoperative recurrence and metastasis of colorectal cancer with Quxie Capsule

Project description:Interventions: The treatment group:Conventional treatment add Quxie capsule;The control group:Quxie capsule was not added to conventional treatment Primary outcome(s): Survival index, 5,10,15 year survival;Factors influencing patient survival rate and disease recurrence and metastasis rate (combined disease, KPS score) Study Design: Parallel

| 2699222 | ecrin-mdr-crc

Study on the characteristics of cold and heat syndrome of colorectal cancer based on intestinal microecology and the precision of intervention scheme for dominant population

Project description:Interventions: Patients with new-onset colonic adenoma:no intervention;Patients with early and mid-stage colorectal cancer before surgery:no intervention;Chemotherapy ± targeted/immunized colorectal cancer patients::no intervention;Patients with advanced colorectal cancer:no intervention Primary outcome(s): Diagnosis and curative effect evaluation scale of cold and heat syndrome in colorectal cancer Study Design: Cohort study

| 106904 | ecrin-mdr-crc

The application and exploration of Fruquintnib combined with TAS-102 and Stereotactic Body Radiotherapy(SBRT)for Third-line and Beyond Treatment of Metastatic Colorectal Cancer

Project description:Interventions: Cohort 1:Fruquintnib combined with TAS-102 and SBRT;Cohort 2:Fruquintnib combined with TAS-102 Primary outcome(s): Progression-free survival assessed by the investigator Study Design: Factorial

| 87000 | ecrin-mdr-crc

TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer

Project description:This is a single-arm, multicentre real-world observational study of TAS-102 in combination with regorafenib or fruquintinib for third-line and above advanced colorectal cancer.

| 69888 | ecrin-mdr-crc

Real-world Study of Patients with Metastatic Colorectal Cancer Receiving Investigational Bevacizumab in Combination with TAS-102 in the Third or Posterior Line

Project description:Interventions: Group 1:Bevacizumab combined with TAS-102 Primary outcome(s): overall survival;disease progress free survival Study Design: Single arm

| 81138 | ecrin-mdr-crc

Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC

Project description:This was a single-arm, prospective study to investigate the safety of cetuximab in combination with trifluridin tipiracil (TAS-102) in the third-line treatment of Chinese patients with RAS wild-type mCRC.

| 2398166 | ecrin-mdr-crc

TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer

Project description:To evaluate the clinical efficacy and safety of TAS-102 combined with bevacizumab and tislelizumab in third-line or above treatment in patients with advanced colorectal adenocarcinoma with liver metastasis.

| 2717618 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data